Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.
GlaxoSmithKline plc Plans Dividend of GBX 19 (GSK)
Receive News & Ratings for GlaxoSmithKline plc Daily
Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.
GlaxoSmithKline plc (LON GSK) traded down 1.06% during trading on Friday, hitting GBX 1490.00. 7,080,333 shares of the stock traded hands. The company’s market cap is GBX 72.83 billion. The firm has a 50-day moving average price of GBX 1,564.93 and a 200 day moving average price of GBX 1,621.93. GlaxoSmithKline plc has a 52-week low of GBX 1,446.50 and a 52-week high of GBX 1,745.56.
TRADEMARK VIOLATION NOTICE: “[[title]]” was originally reported by [[site]] and is owned by of [[site]]. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at [[permalink]].
In related news, insider Manvinder Singh Banga purchased 2,267 shares of the stock in a transaction that occurred on Wednesday, July 26th. The stock was bought at an average cost of GBX 1,599 ($20.76) per share, for a total transaction of £36,249.33 ($47,058.72). Also, insider Patrick Vallance purchased 861 shares of the stock in a transaction that occurred on Friday, July 14th. The stock was bought at an average price of GBX 1,618 ($21.00) per share, with a total value of £13,930.98 ($18,085.14). Over the last 90 days, insiders purchased 3,151 shares of company stock valued at $5,054,922.
Several equities analysts have recently weighed in on the stock. Berenberg Bank lowered their price objective on shares of GlaxoSmithKline plc from GBX 1,885 ($24.47) to GBX 1,835 ($23.82) and set a “buy” rating on the stock in a research note on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.67) price objective on shares of GlaxoSmithKline plc and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Deutsche Bank AG set a GBX 1,610 ($20.90) price objective on shares of GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Tuesday, August 8th. UBS AG set a GBX 1,600 ($20.77) price objective on shares of GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Tuesday, August 1st. Finally, Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Friday, July 28th. Four analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of GBX 1,724 ($22.38).
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.